%0 Journal Article
%A Slavc, Irene
%A Mayr, Lisa
%A Stepien, Natalia
%A Gojo, Johannes
%A Aliotti Lippolis, Maria
%A Azizi, Amedeo A
%A Chocholous, Monika
%A Baumgartner, Alicia
%A Hedrich, Cora S
%A Holm, Stefan
%A Sehested, Astrid
%A Leblond, Pierre
%A Dieckmann, Karin
%A Haberler, Christine
%A Czech, Thomas
%A Kool, Marcel
%A Peyrl, Andreas
%T Improved Long-Term Survival of Patients with Recurrent Medulloblastoma Treated with a 'MEMMAT-like' Metronomic Antiangiogenic Approach.
%J Cancers
%V 14
%N 20
%@ 2072-6694
%C Basel
%I MDPI
%M DKFZ-2022-02563
%P 5128
%D 2022
%X Medulloblastoma (MB) recurrence is usually incurable despite intensive therapy including high-dose chemotherapy. An evolving alternative approach to conventional chemotherapy aims at interfering with tumor angiogenesis at different levels. We report on a novel combinatorial metronomic antiangiogenic approach. The study is a retrospective observational study of 29 consecutive patients with first or multiple recurrences prospectively treated according to the MEMMAT strategy ('MEMMAT-like') before the formal protocol (MEMMAT; ClinicalTrials.gov Identifier: NCT01356290) started. The study period was 11/2006 to 06/2016. Treatment consisted of daily oral thalidomide, fenofibrate, celecoxib, and alternating 21-day cycles of low-dose oral etoposide and cyclophosphamide supplemented by IV bevacizumab and intraventricular therapy consisting of alternating etoposide and liposomal cytarabine. Median overall survival (OS) after recurrence for the whole group was 29.5 months, OS was 48.3 ± 9.3
%K MEMMAT (Other)
%K antiangiogenic therapy (Other)
%K bevacizumab (Other)
%K intraventricular therapy (Other)
%K low-dose oral therapy (Other)
%K medulloblastoma recurrence (Other)
%K metronomic therapy (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:36291912
%R 10.3390/cancers14205128
%U https://inrepo02.dkfz.de/record/182306